Corona Remedies IPO Allotment Status Check Kaise Kare – Live Updates December 2025

Corona Remedies IPO allotment status is now live for investors who applied during the subscription period. The pharmaceutical company’s Rs 655.37 crore public issue closed on December 10, 2025 with record breaking subscription numbers. Investors can now check their allotment status on Bigshare Services website, BSE and NSE portals using their PAN number or application details.

The IPO received massive demand from all categories with retail investors subscribing 25 to 30 times, Non Institutional Investors booking 204 times and QIBs at 269 times.

With such high oversubscription, the chances of getting allotment are limited especially for retail investors who may get only 1 lot out of 25 to 30 applications. Shares will be credited to demat accounts by December 12 and listing is scheduled for December 15, 2025 on both BSE and NSE.

The grey market premium currently stands at Rs 270 to 319 which is around 25 to 29 percent above the upper price band of Rs 1062. This shows strong investor confidence in the company’s fundamentals and future prospects.

Corona Remedies is a generic drugs manufacturer with 80 percent revenue coming from exports. The company reported Rs 1202 crore revenue in FY25 with 20 percent year on year growth and profit of Rs 149 crore.

Key Takeaways

• Corona Remedies IPO allotment status is live on December 11, 2025
• Check allotment on Bigshare Services, BSE or NSE websites using PAN or application number
• IPO was subscribed 132 to 144 times overall showing massive demand
• Grey market premium is Rs 270 to 319 indicating strong listing gains expected
• Retail investors may get 1 lot per 25 to 30 applications due to oversubscription
• Shares will credit by December 12 and listing date is December 15, 2025
• Refund process will complete by December 12 for ASBA and December 13 for non ASBA

Also Read: Fixed vs Floating Home Loan Rates in India: When to Choose Which Based on RBI Cycles

Corona Remedies IPO Allotment Status Check Karne Ka Tarika

Investors who applied for Corona Remedies IPO can check their allotment status through three official platforms. The process is simple and takes only 5 to 10 minutes. You need your PAN number, application number or demat account details to check the status.

Bigshare Services Website Par Check Kare

Bigshare Services is the official registrar for Corona Remedies IPO. This is the fastest method to check your allotment status. Visit the Bigshare website and select Corona Remedies IPO from the dropdown menu. Enter your PAN number or choose DP ID with Client ID option. You can also use application number with DP ID. Complete the captcha verification and click search button. Your allotment status will show immediately with number of shares allocated if you got allotment.

BSE Portal Se Status Dekhe

BSE also provides allotment checking facility for all IPOs. Go to BSE allotment page and select equity as issue type. Choose Corona Remedies IPO from the dropdown list. Enter your application number or PAN number in the given field. Complete the captcha verification by clicking I am not a robot checkbox. Submit the form and your status will display on screen showing whether shares are allotted or not.

NSE Website Par Verify Kare

NSE offers another option to check Corona Remedies IPO allotment status. Visit NSE IPO allotment page and click on IPO allotment status option. Select Corona Remedies Ltd from the company list. Enter your PAN or application number as per your choice. Verify the captcha code and search for results. The system will show your allotment details instantly.

IPO Subscription Details Aur Demand Analysis

Corona Remedies IPO opened for subscription on December 8 and closed on December 10, 2025. The price band was set at Rs 1008 to Rs 1062 per share with employee discount of Rs 54 per share. The response from investors was exceptional across all categories.

Retail investors subscribed their quota 25.78 to 30.29 times showing strong interest from individual investors. Non Institutional Investors portion was booked 204 to 220 times which is very high demand from high net worth individuals and companies. Qualified Institutional Buyers subscribed 269 to 293 times demonstrating confidence from mutual funds, insurance companies and foreign investors.

Overall the IPO was subscribed 132 to 144 times making it one of the most successful pharma IPOs in recent times. The company raised Rs 194.86 crore from anchor investors on December 5 before the public issue opened. Major mutual funds like HDFC and SBI participated in anchor round.

Grey Market Premium Aur Listing Expectations

Grey market premium is an unofficial indicator of listing price expectations. As of December 11 morning, Corona Remedies IPO GMP stands at Rs 270 to 319 per share. This means shares are trading 25 to 29 percent above the upper price band of Rs 1062 in grey market.

Parameter	Details
Upper Price Band	Rs 1062
Current GMP Range	Rs 270 to Rs 319
Expected Listing Price	Rs 1332 to Rs 1381
Estimated Listing Gains	25 to 29 percent

The GMP was at Rs 319 on day 3 of bidding but has stabilized around Rs 270 to 300 range. Market experts predict strong listing gains of 25 to 28 percent on debut day. However investors should note that GMP is not official and actual listing price depends on market conditions on December 15.

The pharma sector is showing positive trends with export growth and defensive appeal during market volatility. Peer companies like Sun Pharma have gained 15 percent year to date which supports positive sentiment for Corona Remedies listing.

Company Financials Aur Business Overview

Corona Remedies is engaged in development, manufacturing and marketing of generic drugs and branded formulations. The company focuses on key therapeutic areas including women’s health, cardio diabetes, pain management, urology and multispecialty segments.

In FY25, the company reported revenue of Rs 1202 crore showing 20 percent growth compared to previous year. Profit after tax stood at Rs 149 crore with healthy margin of 12.4 percent. The company generates 80 percent of revenue from generic drug exports positioning it well in the growing global pharma market.

The Indian pharmaceutical market is valued at $50 billion and growing at 10 percent annually. Corona Remedies export focus gives it advantage in this expanding market. Post IPO, promoters will hold 20 percent stake which is locked for 18 months as per regulations.

Refund Process Aur Important Dates

Investors who do not get allotment will receive refund of their application money. For ASBA applications, refund will process by December 12, 2025. Non ASBA applicants will get refund by December 13, 2025. You can track refund status through your bank account or UPI app.

Allotted investors will receive shares in their demat account by December 12. The shares will be available for trading from December 15 when the stock lists on BSE and NSE. If you face any issues with allotment or refund, contact Bigshare Services at toll free number 1800 572 3245 or email at ipo@bigshareonline.com.

The timeline shows efficient processing by the company and registrar. Investors should check their demat account on December 12 to confirm share credit. Those planning to sell on listing day should keep demat account details ready for quick trading.

Investor Sentiment Aur Market Buzz

Social media platforms show positive sentiment around Corona Remedies IPO. About 80 percent of discussions focus on allotment status checks and excitement over high subscription numbers. Investors are praising the company’s strong fundamentals and export oriented business model.

The 144 times subscription is being seen as vote of confidence from institutional and retail investors. Many investors compare it with other recent pharma IPOs and find Corona Remedies attractive due to its established presence in generic drugs segment. However some retail investors express concern about low allotment chances due to massive oversubscription.

Market analysts recommend holding the stock for long term given the company’s growth trajectory and sector tailwinds. The pharma sector is expected to benefit from increasing healthcare demand and government push for generic medicines. Corona Remedies positioning in this space makes it interesting play for investors.

Tags: corona remedies ipo allotment status, corona remedies ipo gmp, bigshare services allotment, ipo allotment check online, corona remedies listing date, pharma ipo 2025, corona remedies share price

About Author